Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

Arthritis and Rheumatism

Volumn 54, Issue 6, 2006, Pages 1987-1994

  Lovell, Daniel J ^a   Reiff, Andreas ^b   Jones, Olcay Y ^c   Schneider, Rayfel ^d   Nocton, James ^e   Stein, Leonard D ^f   Gedalia, Abraham ^g   Ilowite, Norman T ^h   Wallace, Carol A ⁱ   Whitmore, James B ^j   White, Barbara ^j,k,l   Giannini, Edward H ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g LOUISIANA STATE UNIVERSITY   (United States)

^h SCHNEIDER CHILDREN'S HOSPITAL   (United States)

ⁱ SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^j Berlex Laboratories   (United States)

^k MEDIMMUNE   (United States)

^l AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; ETANERCEPT; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; ARTICULAR CARTILAGE; CHILD; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 33745042988     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21885     Document Type: Article

References (13)

1. Giannini EH, Petty RE. Treatment of juvenile rheumatoid arthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1294-310.
2. Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheum 1992;19:1604-7.
3. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-8.
4. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
5. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
6. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001;344:76, 240]. N Engl J Med 2000;343:1586-93.
7. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
8. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
9. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, and the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
10. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
11. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al, and the Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
12. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
13. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.